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Background: Current HIV-1 viral-load assays are too
expensive for resource-limited settings. In some coun-
tries, monitoring of antiretroviral therapy is now more
expensive than treatment itself. In addition, some com-
mercial assays have shown shortcomings in quantifying
rare genotypes.
Methods: We evaluated real-time reverse transcription-
PCR with internal control targeting the conserved long
terminal repeat (LTR) domain of HIV-1 on reference
panels and patient samples from Brazil (n  1186),
South Africa (n  130), India (n  44), and Germany
(n  127).
Results: The detection limit was 31.9 IU of HIV-1
RNA/mL of plasma (>95% probability of detection,
Probit analysis). The internal control showed inhibition
in 3.7% of samples (95% confidence interval, 2.32%–
5.9%; n  454; 40 different runs). Comparative qualita-
tive testing yielded the following: Roche Amplicor vs
LTR assay (n  431 samples), 51.7% vs 65% positives;
Amplicor Ultrasensitive vs LTR (n  133), 81.2% vs
82.7%; BioMerieux NucliSens HIV-1 QT (n  453),
60.5% vs 65.1%; Bayer Versant 3.0 (n  433), 57.7% vs
55.4%; total (n  1450), 59.0% vs 63.8% positives. Intra-/
interassay variability at medium and near-negative con-
centrations was 18%–51%. The quantification range was
50–10 000 000 IU/mL. Viral loads for subtypes A–D, F–J,
AE, and AG yielded mean differences of 0.31 log10
compared with Amplicor in the 103–104 IU/mL range.
HIV-1 N and O were not detected by Amplicor, but
yielded up to 180 180.00 IU/mL in the LTR assay. Viral
loads in stored samples from all countries, compared
with Amplicor, NucliSens, or Versant, yielded regres-
sion line slopes (SD) of 0.9 (0.13) (P <0.001 for all).
Conclusions: This method offers all features of com-
mercial assays and covers all relevant genotypes. It
could allow general monitoring of antiretroviral therapy
in resource-limited settings.
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Antiretroviral therapy (ART)6 can effectively treat dis-
eases caused by HIV-1 infection. Lower ART costs make
treatment programs possible in nonaffluent countries,
where 95% of HIV infections occur (1, 2). ART treatment
should include accurate monitoring of plasma virus con-
centrations (viral load) (2–6). For prevention of mother-
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to-child transmission (PMTCT), virus detection is also
required for testing newborns and mothers’ milk.
Testing for HIV-1 in the context of ART and PMTCT is
best done by molecular methods, e.g., reverse transcrip-
tion-PCR (RT-PCR), nucleic acid sequence–based ampli-
fication (NASBA), or branched DNA (bDNA) assays
(4, 5, 7–10). Because of the high diversity of HIV-1, assay
design is extraordinarily demanding. Therefore, viral-
load testing relies almost exclusively on expensive com-
mercial tests. With decreasing prices for drugs in many
countries, therapy monitoring has become more expen-
sive than the treatment itself (11, 12), a situation that leads
to insufficient therapy monitoring, suboptimal patient
management, and increased risk for emergence of drug-
resistant virus strains. In addition, because they have been
optimized for strains prevalent in the Northern Hemi-
sphere, many commercial tests are not accurate for testing
“exotic” HIV-1 subtypes found mainly in developing
countries (13, 14). Moreover, some commercial assays are
based on the gag gene, which is too variable for detection
of outlier strains (15 ).
On the basis of our previous experience (15 ), we
developed an inexpensive real-time RT-PCR viral-load
assay that at least equals commercial tests with regard to
technical features and performance. Instead of the gag
gene, it targets the highly conserved long terminal repeat
(LTR) region, thereby providing a spectrum of detectable
and quantifiable genotypes beyond that of current assays.
Materials and Methods
reference plasma
We obtained WHO international standard reagent [Na-
tional Institute of Biological Standards and Control
(NIBSC)] (16 ) containing 100 000.00 IU of HIV-1, subtype
B, per mL (16 ) and a subtype reference plasma panel
(NIBSC) including lyophilized human plasma samples
containing HIV-1 subtypes A, B, C, D, AE, F, G, H, N, and
O. Another subtype reference plasma panel obtained from
the National Reference Centre for Retroviruses included
aliquots of human plasma containing HIV-1 subtypes A,
B, C, D (2 samples), AE, F, G, and O (2 samples). Viral
loads as determined by the Roche Amplicor system were
provided with this panel.
patient plasmas and commercial viral-load
assays
Human plasma samples from Brazil (n  1186), South
Africa (n  130), India (n  44), and Germany (n  127)
were obtained from ongoing ART programs. All samples
were anonymized, and ethics approval was obtained.
South African samples were collected in Cape Town and
tested by the NucliSens HIV-1 QT NASBA assay
(BioMerieux, formerly Organon Technika) at the Univer-
sity of Cape Town. Indian samples were collected in
Chennai and tested along with the samples from Frank-
furt, Germany, by the Cobas Amplicor Monitor (Ver. 1.5)
assay (Roche) at the University of Frankfurt. Brazilian
samples were collected in Bahia (northeastern Brazil),
Espiritu Santo (eastern Brazil), or Rio Grande do Sul
(southern Brazil), respectively, and tested at these places
by either the BioMerieux HIV-1 QT, Roche Amplicor, or
Versant HIV-1 V 3.0 bDNA assay (Bayer). All materials
were stored at 20 °C after initial viral-load testing and
were transferred to the Bernhard Nocht Institute, where
testing with the real-time LTR assay was done. LTR
testing for all samples from Brazil was done by Brazilian
laboratory staff during a 4-week training session at the
Bernhard Nocht Institute.
The following quantification ranges were provided by
the manufacturers of the commercial assays: Amplicor
standard protocol, 400–750 000 IU/mL; Amplicor ultra-
sensitive protocol, 50–75 000 IU/mL; BioMerieux
NucliSens, 80–10 000 000 IU/mL; Versant, 50–500 000
IU/mL.
oligonucleotide design
A nucleic acid sequence alignment was set up that con-
tained all LTR sequences present in the Los AlamosNational
Laboratory database by 2002 (reproduced in Electronic File
1, which can be found in the Data Supplement accompa-
nying the online version of this article at http://
www.clinchem.org/content/vol52/issue7/). Three con-
served domains, necessary for binding of a probe and 2
flanking primers, were identified on inspection of the
alignment, as current primer design software (Primer
Express; Applied Biosystems) yielded no results. Two
different candidate probes were defined in the middle
conserved domain (region 575–612). In the flanking po-
tential primer-binding sites (regions 520–548 and 625–
653), up to 10 different variations of oligonucleotides per
site were ordered and tested experimentally in each
possible combination with both of the 2 candidate probes.
The most efficient combination of oligonucleotides
showed 3 mismatched nucleotide (nt) residues in the
probe-binding domain in HIV-1 subtype O (nucleotides
580, 586, and 587), which were compensated for by use of
an additional 5-nuclease probe (see below). Because of
the high degree of conservedness at the chosen oligonu-
cleotide binding domains, no additional mismatch com-
pensation was necessary.
lyophilized full-virus quantification
calibrator
A storable, calibrated quantification calibrator was gener-
ated for routine use. Cell-culture–derived HIV-1, subtype
B, strain NL4–3, was inoculated in fresh-frozen human
plasma, diluted, and inoculated in volumes of 10 L in
200 L of buffer AVL. RNA extraction and real-time
RT-PCR testing were conducted as described below. After
an initial limiting dilution series, concentrations of 1, 2, 3,
and 4 log10 above the detection limit were defined as 1,
10, 100, and 1000 PCR units (PCRU), respectively. Stocks
of these concentrations were generated in large volumes,
divided into 10-L aliquots, and lyophilized in vacuum
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glass tubes. To calibrate the stocks, the contents of each of
4 replicate glass tubes of each concentration were com-
pletely redissolved in 200 L of buffer AVL and extracted
as described above. In parallel, 4 replicate samples of
human plasma containing 5000 IU of WHO HIV-1 inter-
national standard were treated like patient plasmas and
tested by the ultrasensitive protocol. After obvious outli-
ers were eliminated, we defined the lyophilized plasma
samples as calibrators in the real-time PCR software and
entered concentrations in terms of PCRU. The mean
PCRU value obtained for the WHO standard was then
used to determine a correction factor for the conversion of
PCRU to WHO standard IU values. The correction factor
was readjusted for each new lot of stock preparations. For
up to at least 4 months, the maximum storage duration,
no loss in RNA concentration was perceivable. Systematic
storage studies were not done because the stability of HIV-1
and other enveloped viruses in lyophilized plasma has been
confirmed several times [see, for example, Refs. (16–20)].
synthetic hiv-1 rna
The LTR PCR fragment (see below) was ligated into a pCR
2.1 plasmid vector and cloned in Escherichia coli by means
of a pCR 2.1-TOPO TA cloning reagent set (Invitrogen).
Plasmids were purified, sequenced, and reamplified with
plasmid-specific primers (M13f-20 and M13r, from the
reagent set) to lower the plasmid background in subse-
quent in vitro transcription. Reamplification products
were transcribed into RNA with the MegaScript T7 in
vitro transcription reagent set as described (Ambion)
(15, 21, 22). After DNase I digestion, RNA transcripts
were purified with Qiagen RNeasy columns and quanti-
fied spectrophotometrically. Results from RT-PCR with
and without reverse transcriptase gave an RNA/DNA
ratio of 106. The synthetic RNA was termed srLTRw. It
should be noted that a much smaller RNA/DNA ratio
was achieved when in vitro transcription reactions were
set up according to the manufacturer’s instructions, using
linearized pLTRw DNA as the template for in vitro
transcription instead of PCR products.
internal control
An alternative probe-binding site was introduced at
HIV-1 nt positions 580–605 (numbering according to
HIV-1 strain HXB2), removing the binding site of the
HIV-1–specific probe at the same time. According to a
previously described strategy (22 ), 2 partial amplicons
were generated by use of primer IcS (5-CAGGAGTGAT-
GGGAAATCAAGGATGCATCATTTTTAATGGAAAA-
GATTTAA-3) in combination with primer LTRAs4
(sequence below), and IcAs (5-GCATCCTTGATTTCCC-
ATCACTCCTGGTAACACTTCACTCCAGTT -
CGAGCCT-3) in combination with primer LTRS3 (se-
quence below), respectively. After extension-PCR with
primers LTRS3/As4, products were TA-cloned, purified,
sequenced, and transcribed as described previously
(15, 21, 22). The RNA/DNA ratio, as determined by PCR
and RT-PCR, was 106. The resulting synthetic RNA was
termed srLTRic. With up to 160 copies of srLTRic added,
a calculated 4.8 copies of HIV-1 RNA were still detectable
in the same reaction in 5 of 5 parallel assays. From 320
copies of internal control onward, signal strength for
HIV-1 decreased. Eighty copies of srLTRic per reaction
was chosen as the working concentration, which did not
interfere with the detection of 50 IU/mL HIV-1 in 24 of 24
reactions, as confirmed by testing of the WHO interna-
tional standard.
ultrasensitive extraction of hiv-1 rna from
plasma
We treated 1.2 mL of cleared plasma with centrifugation
for 1 h at 21 000g in a benchtop centrifuge. Supernatants
were removed completely, and virus pellets were lysed
directly in 200 L of buffer AVL (Qiagen Viral RNA Mini
Kit). To the lysed pellets we added 200 L of ethanol (990
mL/L); after mixing, we loaded the mixture on a Qiagen
viral RNA minicolumn. Elution was with 50 L of buffer
AVE at 80 °C. In routine testing, buffer AVL was supple-
mentedwith internal control srLTRic at 2000 copies/mL (see
below) and stored for up to 5 days at room temperature.
quantification of hiv-1 viral load by one-step
real-time rt-pcr
A 50-L reaction contained 10 L of RNA extract, 1
reaction buffer (Access RT-PCR reagent set; Promega), 2
mM magnesium sulfate, 200 M each deoxynucleotide
triphosphate, 600 nM primer LTR S4 (5-AAGCCT-
CAATAAAGCTTGCCTTGA-3; nt 520–543 of HIV-1 B
reference strain HXB2), 400 nM primer LTR As3 (5-
GTTCGGGCGCCACTGCTAG-3; nt 629–647), 50 nM
probe LTRP1 (5-FAM-TCTGGTAACTAGAGATCCCT-
CAGACC-Black Hole Quencher 1–3, where FAM is 6-
carboxyfluorescein; nt 580–605), 50 nM probe LTRP2 (5-
FAM-CCTGGTGTCTAGAGATCCCTCAGACC-Black Hole
Quencher 1-3 1; nt 580–605), 100 nM probe YFPY (5-
Yakima Yellow-ATCGTTCGTTGAGCGATTAGCAG-Black
Hole Quencher 1-3; artificial binding site), 1 L each of
AMV and Tfl enzyme preparations (Promega Access re-
agent set), and 1 M 6-carboxy-X-rhodamine (ROX) internal
reference dye (all dyes, primers, and probes from Tib Mol-
biol).
Thermal cycling was as follows: 48 °C for 20 min; 94 °C
for 2 min; 12 cycles of 95 °C for 10 s and 62 °C for 30 s; 40
cycles of 94 °C for 10 s and 56 °C for 40 s. Cycling was
performed in either Applied Biosystems 7700 or 7000 SDS
instruments with no perceivable difference in results.
Fluorescence was read out in the 56 °C step of the final
segment of the cycling program. The fluorescence at the
VIC® and FAM wavelengths was analyzed separately
with (ABI 7700) or without (ABI 7000) normalization with
the ROX dye. In the ABI 7700, the baseline area was
routinely defined in cycles 1 to 11. In the ABI 7000, the
“auto baseline” mode was used for data analysis. In
general, calibration curves were used as automatically
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obtained from the operation software of the real-time
RT-PCR systems. In some individual runs, manual read-
justments of the threshold line had to be made according
to the fluorescence noise in the negative controls. When
the low–copy-number reaction of the calibration curve
failed, this was taken as a sign of insufficient sensitivity,
and the whole run was repeated. All patient data pre-
sented are for single determinations, i.e., no duplicate
testing was done.
For those reactions that did not yield FAM amplifica-
tion signals, the VIC amplification signal was inspected.
When the signal was negative or was delayed against the
mean VIC signal in the negative plasma controls by 2 or
more cycles, the respective sample was considered invalid
because of PCR inhibition. Such samples were repro-
cessed and retested in original concentration as well as
after dilution 1:10 in plasma from an HIV-negative donor.
statistical methods
The Statgraphics plus (Ver. 5.1) software package (Manugis-
tics) was used for all statistical analyses described.
Results
Because of HIV-1 variability, primer design for the real-
time LTR RT-PCR was based on a comprehensive nucleic
acid alignment with binding domains of maximal con-
servedness. We optimized reaction chemistry and imple-
mented a thermal cycling protocol with a precycle element
to increase the amplification stringency (23). After optimi-
zation, tests showed high sensitivity with synthetic HIV-1
RNA srLTRw, with detection of 1–5 copies per reaction.
We tested the quantification range with a dilution
series of srLTRw. Up to 4  109 copies of RNA per
reaction, corresponding to 1.6  107 copies/mL of plasma
sample, were quantified with a correlation coefficient
between expected logarithmic copy numbers and ob-
served threshold cycle values of 1.0.
To prevent PCR inhibition from interfering with accu-
rate quantification, we designed a competitive internal
control that used the same amplification primers as HIV-1
and was detected by a probe of different sequence com-
position and different fluorescent labeling. The internal
control was added to all reactions at the same step as the
addition of lysis buffer. After extensive experimental
evaluation, we adjusted the working concentration to 80
copies per assay, or 400 copies per RNA preparation.
We determined the assay limit of detection by diluting
the WHO HIV-1 international standard in human fresh-
frozen plasma to 11, 33, 100, 1000, 10 000, and 100 000
IU/mL. Plasma containing each concentration was ex-
tracted in 4 parallel ultrasensitive RNA preparations, and
each of these was tested in 4 replicate RT-PCR assays,16
data points per concentration. No dropout in HIV-1
detection in 16 parallel reactions was observed from 100
copies/mL upward. We performed Probit regression
analysis to determine the projected response rates accord-
ing to a dose–response model (Fig. 1). At a concentration
of 31.9 IU/mL, detection probability was 95% or higher
(95% confidence interval, 24.8–48.1 IU/mL). The limit of
detection was thus slightly higher than that of several
commercial assays for HIV-1 viral load.
We assessed intraassay accuracy with 8 replicate results
for an HIV-1 B plasma containing 1200 IU/mL tested in the
same experiment. The mean viral load was 1117.5 IU/mL,
with a CV of 18% and an SD of 0.09 log10. To confirm that
the assay accurately quantified viral loads close to the
detection limit, we diluted the WHO international work-
ing reagent to 50 IU/mL and assayed it in 18 replicate
tests in the same experiment. The mean measured value
was 51.4 IU/mL with a CV of 51% and a SD of 0.27 log10.
Because this deviation was compatible with clinical
application, the lower limit of the quantification range
was defined at 50 copies/assay. Considering the upper
limit of the 7700 SDS operation software in analyzing high
concentrations without a need to change analysis set-
tings, the total quantification range was defined as 50–
10 000 000 IU/mL.
We assessed interassay accuracy by testing 2 plasma
samples to which HIV-1 B had been added at 9600 and 960
IU/mL, respectively, in 20 different experiments each.
The mean measured quantities were 10 656 and 986
IU/mL, respectively. The CVs were of 39% and 41%,
respectively, with SDs of 0.17 and 0.23 log10.
Because our assay was intended to detect a broader
spectrum of viral subtypes than gag-based assays, we
assessed the efficiency with which different subtypes of
HIV-1 were amplified by testing 2 different subtype
reference panels containing all relevant strains of HIV-1
groups M, O, and N and 12 plasma samples from patients
infected with non-B subtypes, which provided genotypes
not available in the reference panels, e.g., circulating
recombinant forms AE and AG and subtype J.
Fig. 1. Probit regression analysis to determine the limit of detection of
the LTR assay.
Probability (y axis) is plotted against RNA concentration in 16 parallel test
samples per data point (x axis). The plot depicts the observed proportion of
positive results in parallel experiments (), as well as the derived predicted
proportion of positive results at a given input concentration of RNA. The solid line
is the prediction, and the dashed lines are the 95% confidence limits for the
prediction. Note that the tested range of concentrations extends farther than
shown here (see the text).
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We expected test variation to occur preferably in the
low and medium ranges of virus concentrations; we
therefore diluted high-concentration reference samples in
human fresh-frozen plasma to concentrations of 1000–
10 000 copies/mL and then measured viral loads with the
Roche Cobas Amplicor (Ver. 1.5) and LTR assays (Fig. 2).
Fig. 2. Testing of 2 different subtype reference panels.
(A), Panel 1, German National Reference Centre for Retroviruses; Panel 2, NIBSC panel. (B), plasma samples from patients with non-B HIV-1. f, viral load as determined
by real-time RT-PCR LTR assay; , viral load as determined by Roche Cobas Amplicor (Ver. 1.5). The log10 differences in viral loads are plotted at the bottom of both
panels. Letters displayed along the x axis of each panel are identifiers of HIV strains present in the tested patients. , not detected.
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None of the samples containing HIV-1 subtypes O and
N was detected by the Roche Amplicor, but all yielded
viral-load results with the LTR assay. When we omitted
the subtype N and O samples, the mean logarithmic viral
loads were almost identical with both assays (3.57 and
3.60 by the Amplicor and LTR assays, respectively; differ-
ence insignificant in the t-test and Wilcoxon two-sample
test). In most individual samples, the differences of viral
loads were 0.5 log10 (Fig. 2). Viral loads in individual
samples contained in the reference panels differed by 0.26
Fig. 3. Correlation of viral loads as determined by real-time RT-PCR LTR assay (y axis) and commercial (comparison) assays (x axis) in samples from
different countries.
(A), samples from South Africa, assayed with the BioMerieux NucliSens NASBA assay. (B), samples from India, assayed with the Roche Amplicor (Ver. 1.5) ultrasensitive
protocol. (C), samples from Brazil assayed with the BioMerieux NucliSens NASBA assay. (D), samples from Brazil, assayed with the Bayer Versant (Ver. 3.0) bDNA
assay. (E), samples from Brazil, assayed with the Roche Amplicor (Ver. 1.5) standard protocol. (F), samples from Germany, assayed with the Roche Amplicor (Ver. 1.5)
ultrasensitive protocol. Each panel shows the number of samples included in the analysis; these samples were selected to be within the linear ranges of both the LTR
assay and the respective comparison assays (refer to Materials and Methods for details).
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log10, on average; those in individual patient samples
differed by 0.37 log10, on average. In all samples, the mean
difference of paired viral loads was 0.31 log10.
We next determined the quantitative correlation with
other viral-load assays. Because our assay was intended for
application in resource-limited countries with high HIV-1
prevalence, evaluation included patients from such regions.
Stored samples from Germany (n  127), Brazil (n  1186),
SouthAfrica (n 130), and India (n 44) were available. All
samples had been tested previously by either the Cobas
Amplicor Monitor (Ver. 1.5) RT-PCR assay from Roche, the
NucliSens HIV-1 QT NASBA assay from BioMerieux, or
the Versant HIV-1 bDNA assay from Bayer. All samples
were then quantified by real-time LTR RT-PCR. For
regression analyses, those samples that had results below
or above the quantification ranges of either the comparison
method or the LTR assay were excluded. As shown in Fig. 3,
LTR real-time RT-PCR correlated well with all of the com-
mercial viral-load assays. Regression line slopes in all sam-
ple panels were in the range (SD) of 0.9 (0.13), indicating
highly significant correlations (P 0.001 for all).
Because regression analysis can only compare samples
in which results from both tests are within the quantifi-
cation ranges of each test, respectively, it did not reflect
differences in overall clinical sensitivity. To compare the
detection rates of the LTR assay with those of commercial
tests, we collected qualitative results from all available
samples, as shown in Table 1. The rate of positive results
in all (n  43) samples tested with the Roche Amplicor
conventional protocol was 51.7% compared with 65%
when the same samples were tested with the real-time
LTR assay. The corresponding numbers (percentage pos-
itive with the comparison method/percentage positive
with LTR assay) for the other methods were as follows:
Roche Amplicor ultrasensitive (n  133 samples), 81.2%
vs 82.7% for the LTR assay; NucliSens QT (n 453), 60.5%
vs 65.1%; Bayer Versant (n  43), 57.7% vs 55.4%; total
(n  1450), 59.0% vs 63.8%. Thus, only the Bayer Versant
appeared to be slightly more sensitive than the LTR
real-time RT-PCR when used for testing clinical samples.
We analyzed 40 different routine quantification runs to
determine the rate of inhibited reactions that occur during
routine viral-load monitoring. Of the 454 samples that did
not yield an HIV-1 signal in these runs, 17 had an
undetectable internal control, or 3.7% inhibited reactions
(95% confidence interval, 2.32%–5.9%) in which a false-
negative result would have been obtained had the internal
control not been included.
To demonstrate the applicability of the new assay for
routine monitoring of patients on ART, we selected 5
individuals in whom viral loads were determined by LTR
real-time RT-PCR before and after start of therapy (Fig. 4).
Over the whole range of viral loads, no predilution of
samples was necessary; all samples were well within the
dynamic range of the assay.
Discussion
ART is now becoming an affordable option in resource-
limited countries, where most HIV-1 infections occur, but
without viral-load monitoring, the spread of drug-resis-
tant virus strains has to be anticipated (12, 24). Unfortu-
nately, current commercial viral-load monitoring assays
were designed for use in affluent industrialized countries
and are thus optimized to work best on HIV-1 subtype B
(13, 14, 25, 26).
Our study results show that LTR is a highly suitable
target gene for quantification of exotic HIV-1 genotypes,
thereby reducing the risk of genotype bias. We tested all
important genotypes of HIV-1, and except for groups N
and O, the overall results of virus quantification with
different assays were highly concordant (27–30).
Inclusion of an inhibition control is important because
inhibited tests cause false results in virus screening. Our
rate of 3.7% inhibited tests is in good concordance with
the few previous studies that have addressed this issue
systematically (15, 31–34). The accuracy of our assay was
equivalent to or better than values observed in earlier
studies on commercial and in-house viral-load assays
(28, 35–37), and the good analytical sensitivity of our
assay allowed a broad quantification range covering the
range of viral loads in both treated and untreated patients.
The major benefit of our method is cost reduction.
Commercial assays are currently offered, even in devel-
oping countries, at prices of approximately US $50.00–
$100.00 per test; for our assay the net price is approxi-
mately US $10.00. With full PCR license fees, costs would
still be approximately US $20.00 per test. Our test is not
a Communaute´ Europe´enne-certified in vitro diagnostic
method, however, and thus cannot be used for commer-
cial diagnostic services under European Union law.
Screening of newborns is required in the context of
PMTCT in developing and emerging countries; therefore,
Table 1. Detection of HIV-1 by real-time LTR RT-PCR assay and by commercial methods.
Result constellation Comparison method used
Comparison method Real-time LTR assay Amplicor standard Amplicor ultrasensitive NucliSens QT NASBA Versant Total
Positive Positive 222 108 257 232 819
Negative Negative 149 23 141 175 488
Positive Negative 1 0 17 18 36
Negative Positive 59 2 38 8 107
Total 431 133 453 433 1450
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many patients require only qualitative PCR testing. Be-
cause most commercial PCR assays do not allow qualita-
tive testing without unnecessary extra information, which
would be less expensive, high costs are a potential barrier
to PMTCT. Our assay can be used for screening of more
than 90 samples per run in a purely qualitative mode
because of its open format. In this mode, the same
reliability and sensitivity are provided as in viral-load
monitoring, with the internal control to assure maximum
sensitivity in each individual reaction.
In conclusion, our method is a highly cost-efficient viral-
load monitoring assay with an open format and reliable
day-to-day operation. In our hands the assay has been
running reliably for 3 years of routine testing. The evalu-
ation cohorts in our study may require alternative viral-
load assays in the near future. South Africa has the largest
population of HIV-infected patients in the world (38, 39)
and has a nationwide public service ART program under-
way (40, 41), requiring urgent reduction in the cost of viral-
load monitoring. The situation is similar in Brazil, where the
absolute number of patients is high and the government is
making highly active ART universally available (42, 43).
Finally, India has one of the fastest growing populations of
HIV-1–positive individuals, and emerging ART programs
will require affordable viral-load testing (44, 45). Consider-
ing the large and increasing populations of individuals
infected with HIV-1 in resource-poor settings, the potential
benefit of an affordable viral-load assay is enormous. The
need for alternative methods is obvious, and our approach
might contribute to making this aim attainable.
Parts of this work were funded by the Brazilian Ministry
of Health (Grant CFA 273/04) and by the German Ministry
of Health, as part of funding the National Reference Centre
for Tropical Infections at the Bernhard Nocht Institute.
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